Eisai GAAP EPS of ¥148.31, revenue of ¥619.95B; reaffirms FY outlook
Source: SeekingAlpha
2026-02-09 06:14:14 ET
More on Eisai:
- Eisai Co., Ltd. 2026 Q3 - Results - Earnings Call Presentation
- Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript
- Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions - Slideshow
- Seeking Alpha’s Quant Rating on Eisai
- Historical earnings data for Eisai
Read the full article on Seeking Alpha
For further details see:
Eisai GAAP EPS of ¥148.31, revenue of ¥619.95B; reaffirms FY outlook
Eisai Co
NASDAQ: ESAIY
ESAIY Trading
0.4% G/L:
$7.56 Last:
973 Volume:
$7.58 Open:
ESAIY Latest News
March 01, 2026 07:49:00 pm
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
February 16, 2026 02:03:00 am
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 09, 2026 11:34:00 pm
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
February 05, 2026 09:31:00 pm
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
